Femasys stock.

Nov 30, 2023 · Read Full Company Summary for FEMY here. View Femasys Inc FEMY investment & stock information. Get the latest Femasys Inc FEMY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA. Stock split history for Femasys since 2021.Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Femasys Inc. Common Stock (FEMY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Femasys Inc FEMY shares surged after the company received FDA 510 (k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube. Infertility has affected an increasing number of women – estimated at 10 million in the U.S., according to the Center for Disease Control.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

Since then, however, the stock has slipped by 47%. Writing on Femasys for Chardan Research, 5-star analyst Keay Nakae takes care to laud “the potential of its next generation products addressing ...Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in …

Femasys-stock Femasys Inc Registered Shs Stock , FEMY 0.95 -0.01 -1.53% After-market 07:34:36 PM EDT 11/17/2023 NAS Add to watchlist 0.96 +0.04 …WebFemasys (NASDAQ:FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an aggregate of 18.11M shares of common stock This prospectus is not an offer to sell.Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in permanent birth control and front-end infertility. Femasys Inc (NASDAQ: FEMY) shares surged after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a Femasys Inc FEMY shares surged after the company received FDA 510 (k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube. Infertility has affected an increasing number of women – estimated at 10 million in the U.S., according to the Center for Disease Control.

Find the latest Femasys Inc. (FEMY) stock quote, history, news and other vital information to help you with your stock trading and investing.

Find the latest SEC Filings data for Femasys Inc. Common Stock (FEMY) at Nasdaq.com.

Femasys saw a decline in short interest in November. As of November 15th, there was short interest totaling 286,700 shares, a decline of 33.0% from the previous total of 427,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will ...Jul 27, 2023 · FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth controlATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ ... Femasys' cash burn of US$10.0m is about 50% of its US$20m market capitalisation. ... and we've picked out 3 warning signs for Femasys that investors should know when investing in the stock. ...Femasys, a medical device company, is set to launch its minimally invasive reproductive health products for women in 2024. ... Its stock ran from $0.33 to an …WebStock analysis for Femasys Inc (FEMY:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Femasys (FEMY) In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Femasys. The company’s shares closed last Wednesday at $1.11.Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional …Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Sep 29, 2023 · Femasys Inc. (NASDAQ: FEMY) shares are trading higher Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13. Shares Outstanding 21.65 M Public Float 19.48 M Yield FEMY is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short Interest (10/31/23) …Web

Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.

Femasys Inc. (FEMY) delivered earnings and revenue surprises of -8.70% and 13.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch - Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - …WebFemasys story: Femasys Inc Shares Close the Day 14.4 percent Lower - Daily Wrap - Nasdaq and other headlines for Femasys StockSep 27, 2023 · Femasys has a market capitalisation of US$22m and burnt through US$11m last year, which is 50% of the company's market value. ... It does not constitute a recommendation to buy or sell any stock ... FEMY Femasys Bull Pennant On 7/13/2021 Jonestrading brokerage Initiated Coverage with a Buy rating and a $8.45 Price Target On 7/13/2021 Chardan Capital brokerage Initiated Coverage with a Buy rating and a $25.00 Price Target How do you explain such a big difference in valuation?Femasys : Corporate Presentation June 2023. Disrupting Convention in Women's Health Through Continuous Innovation. This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not …Nov 18, 2023 · Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.

3 equities research analysts have issued twelve-month price targets for Femasys' shares. Their FEMY share price targets range from $7.00 to $10.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 884.9% from the stock's current price. View analysts price targets for FEMY or ...

Nov 15, 2023 · Femasys-stock; News for Femasys Femasys; ... warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.18 per share expiring one year from issuance and ...

Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.Dec 1, 2023 · Stock analysis for Femasys Inc (FEMY:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Latest SEC filings for Femasys Inc. (FEMY). Entering text into the input field will update the search result belowUnder the terms of the investment, the investors were also issued two series of warrants: warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.18 per ...These promising developments of Femasys’s products further solidify the Buy rating. In another report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $10.00 price ...ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide …WebShares of biomedical firm Femasys soared on Thursday.; Management announced the issuance of a notice of allowance for its patent application. FEMY stock soared on IP protection of its first-of-its ...An Atlanta woman-founded, women's healthcare company plans to raise $40 million in an initial public stock offering. Suwanee-based Femasys Inc. says in plans filed May 14 with the Securities and ...Nov. 30, 2023 5:40 PM ET Femasys Inc. (FEMY) By: Tiyashi Datta, SA News Editor. Femasys ( NASDAQ: FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an ...Overview. Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.On average, Wall Street analysts predict. that Femasys's share price could reach $9.00 by Nov 14, 2024. The average Femasys stock price prediction forecasts a potential upside of 821.19% from the current FEMY share price of $0.98.Description. Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient ...

FEMY Earnings Date and Information. Femasys has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, April 4th, 2024 based off prior year's report dates. Read More.Oct 2, 2023 · Femasys Inc, a medical technology company, has been attracting attention from investors due to its positive stock performance on October 2, 2023. According to data from CNN Money, the company has received favorable price forecasts from four analysts, with a median target of $8.50. The high estimate is $13.00, while the low estimate is $5.00. Publish : 04 Oct 2023, 07:17 PM Update : 04 Oct 2023, 07:17 PM. Femasys (NASDAQ: FEMY) stock is down 50% over night from highs. A reasonable bet would be that FEMY stock will continue to fall back to more reasonable levels. For, as far as we can see at least, this is a flurry of speculation producing far too much movement for the objective ...Instagram:https://instagram. nyse arr newsbest reits to invest in 2023latest news on nvidiatrulieve stocks That’s a massive surge in trading volume compared to Femasys’ daily average of about 3.3 million shares. FEMY stock is up 180.9% as of Tuesday morning after closing out Monday down 63.2% year ...Femasys expects the resulting patent, when issued, will have an anticipated expiration in 2039, at the earliest. In October, Femasys regained compliance with Nasdaq’s minimum bid price requirement, after having received a notice on June 1, 2023 from Nasdaq that they were not in compliance with such requirement. bak stock dividendajgallagher - The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ®, an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed to deliver sperm directly to where conception …ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a suite of product candidates and products that include minimally invasive, in-office technologies for reproductive health, announced that the United States Patent and … ibp Shares of biomedical firm Femasys soared on Thursday.; Management announced the issuance of a notice of allowance for its patent application. FEMY stock soared on IP protection of its first-of-its ...ATLANTA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office ...Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.